ArTS Archivio della ricerca di Trieste

ZAJA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.543
EU - Europa 2.856
AS - Asia 1.518
AF - Africa 23
SA - Sud America 14
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.514
PL - Polonia 886
SE - Svezia 883
HK - Hong Kong 765
CN - Cina 559
IT - Italia 298
BG - Bulgaria 271
IE - Irlanda 246
DE - Germania 90
UA - Ucraina 41
KR - Corea 40
VN - Vietnam 37
IN - India 32
TR - Turchia 27
CA - Canada 26
GB - Regno Unito 25
CH - Svizzera 22
FI - Finlandia 21
BE - Belgio 20
SN - Senegal 17
FR - Francia 15
IL - Israele 14
RU - Federazione Russa 9
JP - Giappone 8
ES - Italia 7
AU - Australia 6
BR - Brasile 6
IR - Iran 6
AT - Austria 5
PE - Perù 5
PK - Pakistan 5
SG - Singapore 5
CZ - Repubblica Ceca 4
LK - Sri Lanka 4
TW - Taiwan 4
BD - Bangladesh 3
DK - Danimarca 3
HR - Croazia 3
MX - Messico 3
NL - Olanda 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
DZ - Algeria 2
EG - Egitto 2
JO - Giordania 2
MY - Malesia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
ID - Indonesia 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
PH - Filippine 1
TH - Thailandia 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 12.962
Salva come PNG Salva come JPEG
Città #
Fairfield 1.609
Warsaw 882
Ashburn 835
Woodbridge 778
Hong Kong 765
Seattle 665
Houston 661
Wilmington 620
Chandler 610
Cambridge 520
Princeton 484
Ann Arbor 291
Sofia 271
Beijing 267
Jacksonville 246
Dublin 243
Boardman 153
San Diego 125
Trieste 120
Seoul 40
Norwalk 37
Dong Ket 36
Redwood City 25
Bremen 23
Nanjing 23
Bern 19
Jinan 18
Washington 18
Brussels 17
Dakar 17
Dearborn 17
Andover 14
Fremont 14
Izmir 14
Helsinki 11
London 11
Toronto 11
Kocaeli 10
Milan 10
Hefei 9
Rome 9
Kochi 8
Monmouth Junction 8
Taiyuan 8
Tianjin 8
Udine 8
Krefeld 7
Kunming 7
Pune 7
Redmond 7
San Bartolomeo in Galdo 7
Shenyang 7
Ardabil 6
Fuzhou 6
Guangzhou 6
Leawood 6
Shanghai 6
Backa 5
Gradisca D'isonzo 5
Hebei 5
Karachi 5
Padova 5
Phoenix 5
Pignone 5
Vienna 5
Zhengzhou 5
Augusta 4
Des Moines 4
Kollam 4
Legnaro 4
New York 4
Tappahannock 4
Venezia 4
Vicenza 4
Antwerpen 3
Basel 3
Casier 3
Changsha 3
Grafing 3
Kandana 3
Lanzhou 3
Moscow 3
Mumbai 3
Nanchang 3
San Francisco 3
San Mateo 3
São Paulo 3
Vancouver 3
Alessandria 2
Amman 2
Bagnolo in Piano 2
Brno 2
Buffalo 2
Buja 2
Chilly-mazarin 2
Dallas 2
Denver 2
Dongguan 2
Edinburgh 2
Frankfurt am Main 2
Totale 10.803
Salva come PNG Salva come JPEG
Nome #
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 307
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival 254
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 249
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. 173
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. 160
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT) 153
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 142
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 141
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? 137
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components 137
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 128
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 128
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 123
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 118
Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? 117
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. 109
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 106
Rituximab for the treatment of type II mixed cryoglobulinemia 105
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 100
Low-dose rituximab in adult patients with primary immune thrombocytopenia 97
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection 96
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice 89
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 89
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 88
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 88
Bendamustine salvage therapy for T cell neoplasms 87
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 87
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 86
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 86
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion 86
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 84
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation 83
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 83
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice 83
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis 83
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 82
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response 81
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 81
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia 79
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab 77
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters 76
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 76
Rituximab in a case of cold agglutinin disease 75
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 75
Management of immune thrombocytopenia in elderly patients 75
Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant 75
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 75
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-κ B pathways 74
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 73
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 73
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 72
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 72
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 70
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics 69
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 69
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 69
Meningeal and cerebral involvement in multiple myeloma patients 68
The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma 68
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study 67
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 67
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 65
Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment 65
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 65
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 64
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 62
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network 62
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 62
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations 62
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 62
Updated international consensus report on the investigation and management of primary immune thrombocytopenia 62
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 62
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL 62
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 61
Combination of Rituximab, Bendamustine and Cytarabine (R-BAC) for Patients With Mantle Cell Non-Hodgkin's ineligible for intensive regimens or autologous transplantation. Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation 61
CD38, BCL-2, PD-1 and PD-1L expression in nodal peripheral T-cell lymphoma (PTCL): Possible biomarkers for novel targeted therapies? 61
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 61
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 60
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 60
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin 60
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 60
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma 60
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies 60
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 60
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 60
B-cell depletion with rituximab as treatment for autoimmune thrombocytopenia 59
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 59
The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease 59
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients 59
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 59
Mycophenolate Mofetil for Immune Thrombocytopenia. Reply 59
Treatment of refractory chronic GVHD with rituximab: a GITMO study 58
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years 58
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia 58
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 58
The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center 57
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials 56
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial 56
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 56
Hepatitis C virus infection (and additional neoplasms) among marginal zone lymphomas 56
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 56
Totale 8.522
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019104 0 0 0 0 0 0 0 0 0 23 50 31
2019/20203.420 19 16 15 46 221 473 769 561 616 290 186 208
2020/20213.372 196 358 336 399 249 354 182 237 104 336 166 455
2021/20222.403 58 271 64 245 18 80 172 110 317 237 109 722
2022/20232.417 309 276 245 181 250 477 11 230 274 39 90 35
2023/20241.706 88 76 143 51 85 219 343 635 46 20 0 0
Totale 13.708